Literature DB >> 21704331

Obesity and weight loss at presentation of lung cancer are associated with opposite effects on survival.

Relin Yang1, Michael C Cheung, Felipe E Pedroso, Margaret M Byrne, Leonidas G Koniaris, Teresa A Zimmers.   

Abstract

BACKGROUND: Lung cancer is the second most common neoplasm and the leading cause of cancer deaths in the United States. In cancer, weight loss and obesity are associated with reduced survival. However, the effect of obesity or weight loss at presentation on lung cancer survival has not been well studied.
MATERIALS AND METHODS: Using an extensive cancer dataset, we identified 76,086 patients diagnosed with lung cancer during the period of 1998-2002, of which 14,751 patients presented with obesity and/or weight loss. We examined the relationship between survival and weight loss or obesity at diagnosis using univariate and multivariate analysis.
RESULTS: Median survival time (MST) for all lung cancer patients was 8.7 mo. Patients presenting with weight loss (15.8%) had shorter MST versus those who did not (6.4 versus 9.2 mo, P < 0.001) and patients with weight loss had significantly shortened MST for all stages and histologic subtypes. In contrast, obese patients at presentation (5.4%) had longer MST relative to non-obese patients (13.0 versus 8.6 mo, P < 0.001), which was significant across all stages and histologic subtypes. Multivariate analysis revealed that the absence of weight loss was an independent, positive predictor of improved survival (HR = 0.087, P < 0.001), while the absence of obesity was an independent predictor of worsened survival in lung cancer (HR = 1.16, P < 0.001).
CONCLUSIONS: Our results demonstrate an inverse relationship between survival and weight loss at presentation and a potentially protective effect of obesity in lung cancer survival, which could be due to greater physiologic reserves, thereby prolonging life by slowing the progress of cancer cachexia.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21704331      PMCID: PMC3154461          DOI: 10.1016/j.jss.2011.04.061

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  33 in total

1.  Body composition and prognosis in chronic systolic heart failure: the obesity paradox.

Authors:  Carl J Lavie; Ahmed F Osman; Richard V Milani; Mandeep R Mehra
Journal:  Am J Cardiol       Date:  2003-04-01       Impact factor: 2.778

2.  Gastric carcinoids: a temporal increase with proton pump introduction.

Authors:  N Hodgson; L G Koniaris; A S Livingstone; D Franceschi
Journal:  Surg Endosc       Date:  2005-10-05       Impact factor: 4.584

3.  Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.

Authors:  Eduardo A Perez; Alan S Livingstone; Dido Franceschi; Caio Rocha-Lima; David J Lee; Nicole Hodgson; Merce Jorda; Leonidas G Koniaris
Journal:  J Am Coll Surg       Date:  2006-04       Impact factor: 6.113

4.  Lower lung cancer mortality in obesity.

Authors:  Chi C Leung; Tai H Lam; Wing W Yew; Wai M Chan; Wing S Law; Cheuk M Tam
Journal:  Int J Epidemiol       Date:  2010-08-12       Impact factor: 7.196

5.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

6.  Forecasting the effects of obesity and smoking on U.S. life expectancy.

Authors:  Susan T Stewart; David M Cutler; Allison B Rosen
Journal:  N Engl J Med       Date:  2009-12-03       Impact factor: 91.245

7.  Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II.

Authors:  W Dana Flanders; Cathy A Lally; Bao-Ping Zhu; S Jane Henley; Michael J Thun
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

8.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

9.  7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly.

Authors:  Eduardo A Perez; Leonidas G Koniaris; Sarah E Snell; Juan C Gutierrez; William E Sumner; David J Lee; Nicole C Hodgson; Alan S Livingstone; Dido Franceschi
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 10.  Pathophysiology of cancer cachexia: much more than host-tumour interaction?

Authors:  Richard J E Skipworth; Grant D Stewart; Cornelis H C Dejong; Tom Preston; Kenneth C H Fearon
Journal:  Clin Nutr       Date:  2007-05-15       Impact factor: 7.324

View more
  34 in total

1.  Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma.

Authors:  Kenneth R Carson; Nancy L Bartlett; Jay R McDonald; Suhong Luo; Angelique Zeringue; Jingxia Liu; Qiang Fu; Su-Hsin Chang; Graham A Colditz
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

2.  Dysphagia prevalence and associated survival differences in older patients with lung cancer: A SEER-Medicare population-based study.

Authors:  Schelomo Marmor; Seth Cohen; Naomi Fujioka; L Chinsoo Cho; Amit Bhargava; Stephanie Misono
Journal:  J Geriatr Oncol       Date:  2020-03-11       Impact factor: 3.599

3.  The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.

Authors:  F Hong; T M Habermann; L I Gordon; H Hochster; R D Gascoyne; V A Morrison; R I Fisher; N L Bartlett; P J Stiff; B D Cheson; M Crump; S J Horning; B S Kahl
Journal:  Ann Oncol       Date:  2014-03       Impact factor: 32.976

4.  The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).

Authors:  Vicki A Morrison; Linda McCall; Hyman B Muss; Aminah Jatoi; Harvey J Cohen; Constance T Cirrincione; Jennifer A Ligibel; Jacqueline M Lafky; Arti Hurria
Journal:  J Geriatr Oncol       Date:  2017-12-08       Impact factor: 3.599

5.  Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.

Authors:  Philippe Atlan; Mohamed Amine Bayar; Emilie Lanoy; Benjamin Besse; David Planchard; Jordy Ramon; Bruno Raynard; Sami Antoun
Journal:  Support Care Cancer       Date:  2017-06-08       Impact factor: 3.603

6.  Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials.

Authors:  Suzanne E Dahlberg; Joan H Schiller; Philip B Bonomi; Alan B Sandler; Julie R Brahmer; Suresh S Ramalingam; David H Johnson
Journal:  J Thorac Oncol       Date:  2013-09       Impact factor: 15.609

7.  Exercise and nutrition interventions in advanced lung cancer: a systematic review.

Authors:  C Payne; P J Larkin; S McIlfatrick; L Dunwoody; J H Gracey
Journal:  Curr Oncol       Date:  2013-08       Impact factor: 3.677

8.  Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer.

Authors:  Jinlu Shan; Yanli Xiong; Dong Wang; Mingfang Xu; Y I Yang; Kan Gong; Zhenzhou Yang; G E Wang; Xueqin Yang
Journal:  Mol Clin Oncol       Date:  2015-02-06

9.  Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC.

Authors:  Sai Yendamuri; Joseph Barbi; Sarabjot Pabla; Cara Petrucci; Achamaporn Punnanitinont; Mary Nesline; Sean T Glenn; Paul Depietro; Antonios Papanicalou-Sengos; Carl Morrison; Grace K Dy; Peter L Elkin
Journal:  J Thorac Oncol       Date:  2019-08-06       Impact factor: 15.609

10.  Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC).

Authors:  Muhammad Furrukh; Mansour Al-Moundhri; Khawaja F Zahid; Shiyam Kumar; Ikram Burney
Journal:  Sultan Qaboos Univ Med J       Date:  2013-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.